IL3RA and neoplasm: Although several agents targeting FLT3, CD123 or KIT are under development, preclinical and clinical reports have highlighted the risk of myelosuppression due to on-target/off-tumour toxicity, and this issue is expected to be exacerbated when a prolonged anti-leukaemia effect is desirable or when multiple antigens are targeted.